Abstract Hematologic adverse events are common dose-limiting toxicities in drug development. Classical animal models for preclinical safety assessment of immunotherapies are often limited due to insufficient cross-reactivity with non-human homologous proteins, immune system differences, and ethical considerations. Therefore, we evaluate a human bone marrow (BM) microphysiological system (MPS) for its ability to predict expected hematopoietic liabilities of immunotherapeutics.
Robert Mader
Chicago
As seen in:
LinkedIn,
Nature,
Wiley,
Wiley Online Library,
Informa,
Contracting Business,
Contractor,
HPAC Engineering,
PHCP Pros,
RSES Journal
Journalist focused on water and energy conservation. Editor of Plumbing Engineer magazine. #Contractors #Engineers #Plumbing #HVAC. Tweets/opinions are mine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Robert
Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack